Click Therapeutics Stock
Digital Therapeutics Applications
Sign up today and learn more about Click Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Click Therapeutics Stock
Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults.
Magellan Health Services
Chief Executive Officer
David Benshoof Klein
Chief Technology Officer
mobihealthnews - Feb, 26 2021Boehringer Ingelheim and Click Therapeutics talk about what makes DTx and pharma partnerships tick
buff - Feb, 25 2021Otsuka, Click trial digital depression therapy with Google
trib - Sep, 15 2020Boehringer Ingelheim and Click Therapeutics ink a $500 million deal
businesswire - Feb, 11 2020Click Therapeutics Announces Appointment of Top Healthcare Executives Muzammil Mansuri and Jeffrey Berkowitz as Senior Strategic Advisors and Formation of Payer Advisory Board
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase